The 10-second takeaway
For the quarter ended June 30 (Q2), Invacare beat expectations on revenues and missed expectations on earnings per share.
Compared to the prior-year quarter, revenue shrank significantly. Non-GAAP earnings per share dropped to a loss. GAAP loss per share grew.
Gross margins grew, operating margins shrank, net margins dropped.
Invacare recorded revenue of $351.8 million. The one analyst polled by S&P Capital IQ expected revenue of $320.0 million on the same basis. GAAP reported sales were 23% lower than the prior-year quarter's $454.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
EPS came in at -$0.27. The two earnings estimates compiled by S&P Capital IQ predicted -$0.20 per share. Non-GAAP EPS were -$0.27 for Q2 against $0.30 per share for the prior-year quarter. GAAP EPS were -$0.29 for Q2 compared to -$0.06 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.
For the quarter, gross margin was 28.2%, 50 basis points better than the prior-year quarter. Operating margin was -1.6%, 470 basis points worse than the prior-year quarter. Net margin was -2.6%, 220 basis points worse than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $325.0 million. On the bottom line, the average EPS estimate is -$0.17.
Next year's average estimate for revenue is $1.33 billion. The average EPS estimate is -$1.00.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 51 members out of 65 rating the stock outperform, and 14 members rating it underperform. Among 21 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 15 give Invacare a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Invacare is buy, with an average price target of $20.00.
Is Invacare the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Invacare to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.